Reckitt Benckiser Group PLC (OTCMKTS:RBGLY - Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $15.20 and last traded at $15.20, with a volume of 162805 shares changing hands. The stock had previously closed at $15.18.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on RBGLY shares. Sanford C. Bernstein upgraded shares of Reckitt Benckiser Group from a "hold" rating to a "strong-buy" rating in a report on Thursday, June 5th. Royal Bank Of Canada reiterated an "outperform" rating on shares of Reckitt Benckiser Group in a report on Friday, July 25th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy".
Check Out Our Latest Stock Report on Reckitt Benckiser Group
Reckitt Benckiser Group Stock Performance
The stock's fifty day moving average is $13.92 and its two-hundred day moving average is $13.37. The company has a current ratio of 0.56, a quick ratio of 0.39 and a debt-to-equity ratio of 1.01.
Reckitt Benckiser Group Cuts Dividend
The business also recently disclosed a dividend, which will be paid on Thursday, September 25th. Shareholders of record on Monday, August 11th will be issued a $0.2106 dividend. This represents a dividend yield of 341.0%. The ex-dividend date is Friday, August 8th.
Reckitt Benckiser Group Company Profile
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Further Reading
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
